Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study

Theoretical Biology and Medical Modelling

Volumn 10, Issue 1, 2013, Pages

  Fijorek, Kamil ^a   Patel, Nikunjkumar ^b   Klima, Łukasz ^c   Stolarz Skrzypek, Katarzyna ^c   Kawecka Jaszcz, Kalina ^c   Polak, Sebastian ^b,c  

^a CRACOW UNIVERSITY OF ECONOMICS   (Poland)

^b CERTARA UK LIMITED   (United Kingdom)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Circadian rhythm; Drugs cardiotoxicity; Heart rate; Regression modelling

Indexed keywords

ANIMALIA;

HETEROCYCLIC COMPOUND; MOXIFLOXACIN; QUINOLINE DERIVATIVE;

ADULT; AGED; AGING; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CHANNEL GATING; CIRCADIAN RHYTHM; DRUG EFFECT; FEMALE; HEART ARRHYTHMIA; HEART RATE; HUMAN; IC 50; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DEVELOPMENT;

ADULT; AGED; AGING; ANIMALS; ARRHYTHMIAS, CARDIAC; AZA COMPOUNDS; CIRCADIAN RHYTHM; FEMALE; HEART RATE; HUMANS; INHIBITORY CONCENTRATION 50; ION CHANNEL GATING; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; QUINOLINES; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84873437083     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-10-7     Document Type: Article

References (32)

1. Preclinical cardiac safety assessment of drugs. Hanton G, Drugs R&D 2007 8 4 213 228 23463334 (Pubitemid 47026339)
2. The use of induced pluripotent stem cells in drug development. Inoue H, Yamanaka S, Clin Pharmacol Ther 2011 89 655 661 10.1038/clpt.2011.38 21430656
3. ICH 2005 International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (ICH E14) Rockville, Md: US Department of Health and Human Services Food and Drug Administration 2005
4. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG, Cardiovasc Res 2003 58 1 32 45 10.1016/S0008-6363(02)00846-5 12667944 (Pubitemid 36351620)
5. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Yao X, Anderson DL, Ross SA, Lang DG, Desai BZ, Cooper DC, Wheelan P, McIntyre MS, Bergquist ML, MacKenzie KI, Becherer JD, Hashim MA, Br J Pharmacol 2008 154 7 1446 1456 10.1038/bjp.2008.267 18587422
6. ToxComp.net www.tox-comp.net; accessed 07-02-2013
7. ToxComp-in vitro-in vivo extrapolation system for the drugs proarrhythmic potency assessment. Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A, Com Cardiol 2012 39 789 793
8. Modeling and simulation approach for assessing proarrhythmic potency of the non-cardiological drugs. Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A, Com Cardiol 2012 39 761 765
9. In silico prediction of the drug overdose consequences at the heart electrophysiology level. Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A, Com Cardiol 2012 39 889 893
10. Circadian Rhythms in Man. A self-sustained oscillator with an inherent frequency underlies human 24-hour periodicity. Aschoff J, Science 1965 148 3676 1427 1432 10.1126/science.148.3676.1427 14294139
11. Reference values for circadian rhythms of 98 variables in clinically healthy men in the fifth decade of life. Kanabrocki EL, Sothern RB, Scheving LE, Vesely DL, Tsai TH, Shelstad J, Cournoyer C, Greco J, Mermall H, Ferlin H, Chronobiol Int 1990 7 5-6 445 461 2097078
12. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. Piotrovsky V, AAPS J 2005 7 3 609 E624 10.1208/aapsj070363 16353940 (Pubitemid 41631729)
13. Circadian rhythm of the signal averaged electrocardiogram and its relation to heart rate variability in healthy subjects. Nakagawa M, Iwao T, Ishida S, Yonemochi H, Fujino T, Saikawa T, Ito M, Heart 1998 79 5 493 496 9659198 (Pubitemid 28215830)
14. Circadian rhythm of heart rate and heart rate variability. Massin MM, Maeyns K, Withofs N, Ravet F, Gerard P, Arch Dis Child 2000 83 179 182 10.1136/adc.83.2.179 10906034
15. The circadian pattern of cardiac autonomic modulation in a middle-aged population. Li X, Shaffer ML, Rodriguez-Colon S, He F, Wolbrette DL, Alagona P Jr, Wu C, Liao D, Clin Auton Res 2011 21 3 143 150 10.1007/s10286-010-0112-4 21240538
16. Circadian Profile of Cardiac Autonomic Nervous Modulation in Healthy Subjects: Differing Effects of Aging and Gender on Heart Rate Variability. Bonnemeier H, Richardt G, Potratz J, Wiegand UK, Brandes A, Kluge N, Katus HA, J Cardiovasc Electrophysiol 2003 14 791 799 10.1046/j.1540-8167.2003.03078.x 12890036 (Pubitemid 36994094)
17. Heart rate variability during waking and sleep in healthy males and females. Eisenbruch S, Harnish MJ, Orr WC, Sleep 1999 22 8 1067 1071 10617167 (Pubitemid 30173981)
18. Circadian variation of heart rate variability among welders. Cavallari JM, Fang SC, Mittleman MA, Christiani DC, Occup Environ Med 2010 67 10 717 719 10.1136/oem.2010.055210 20798005
19. Circadian rhythm of heart rate in myotonic dystrophy. Cugini P, Bernardini F, Cardarello CM, Coda S, Curione M, De Francesco GP, De Rosa R, Dutto L, Fontana S, Mammarella A, Paoletti V, Paradiso M, Pellegrino AM, J Clin Basic Cardiol 2000 3 3 181 186
20. Circadian periodicity of heart rate variability in hospitalized angor patients. D'Negri CE, Marelich L, Vigo D, Acunzo RS, Girotti LA, Cardinali DP, Siri LN, Clin Auton Res 2005 15 3 223 232 10.1007/s10286-005-0280-9 15944873 (Pubitemid 40909712)
21. PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals. Goldberger AL, Amaral LAN, Glass L, Hausdorff JM, Ivanov PC, Mark RG, Mietus JE, Moody GB, Peng C-K, Stanley HE, Circulation 2000 101 23 215 220 10.1161/01.CIR.101.23.e215
22. A model for human ventricular tissue. ten Tusscher KH, Noble D, Noble PJ, Panfilov AV, Am J Physiol Heart Circ Physiol 2004 286 4 1573 H1589 14656705
23. Virtual population generator for human cardiomyocytes parameters. In silico drug cardiotoxicity assessment. Polak S, Fijorek K, Glinka A, Wisniowska B, Mendyk A, Toxicol Mech Methods 2012 22 1 31 40 10.3109/15376516.2011.585477 22150010
24. Inter-individual variability in the preclinical drug cardiotoxic safety assessment-analysis of the age-cardiomyocytes electric capacitance dependence. Polak S, Fijorek K, J Cardiovasc Transl Res 2012 5 3 321 332 10.1007/s12265-012-9357-8 22411323
25. Reevaluation of moxifloxacin in pharmacokinetics and their direct effect on the QT interval. Grosjean P, Urien S, J Clin Pharmacol 2012 52 329 338 10.1177/0091270011398361 21415283
26. Pharmacokinetics, safety, and tolerability of ascending single doses of Moxifloxacin, a new 8-methoxy Quinolone, administered to healthy subjects. Stass H, Dalhoff A, Kubitza D, Schuhly U, Antimicrob Agents Chemother 1998 42 8 2060 2065 9687407 (Pubitemid 28363093)
27. Tox-database.net: a curated resource for data describing chemical triggered in vitro cardiac ion channels inhibition. Polak S, Wisniowska B, Glinka A, Polak M, BMC Pharmacol Toxicol 2012 13 6 1 13 22946996
28. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Alexandrou AJ, Duncan RS, Sullivan A, Hancox JC, Leishman DJ, Witchel HJ, Leaney JL, Br J Pharmacol 2006 147 8 905 916 10.1038/sj.bjp.0706678 16474415
29. A step towards characterisation of electrophysiological profile of torsadogenic drugs. Champeroux P, Ouillé A, Martel E, Fowler JS, Maurin A, Richard S, Le Guennec JY, J Pharmacol Toxicol Methods 2011 63 3 269 278 10.1016/j.vascn.2011.01.001 21224008
30. Die sytolendauer in elektrokardiogramm bei normalen menschen und beiherzkranken. Fridericia LS, Acta Med Scand 1920 53 469 486
31. R Development Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing Vienna, Austria: 3-900051-07-0 2012 http://www.R-project.org/
32. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. Garnett C, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornoe CW, Wang Y, Zhu H, Gobburu JV, J Clin Pharmacol 2008 48 13 18 10.1177/0091270007307881 18094216 (Pubitemid 350292272)